Does LNSR pay a dividend and is it safe?

LENSAR Inc. (LNSR) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / LNSR / dividends

MBOT (29) QTEX (36) SKIN (32) LUCD (39) ⌘ Pro Terminal →

LENSAR Inc. (LNSR) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?

LNSR last traded at $5.67 (-2.91% on volume of 70,194 shares), positioning the stock -19.46% below its 50-day simple moving average ($7.04) and -23.58% below its 200-day simple moving average ($7.42). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 9.0% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($5.27 to $6.07).

$5.67 -2.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.63

LENSAR Inc. (LNSR) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $71.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNSR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $5.67 (-2.91% 1D, market cap $71.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LNSR ranks #1003 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LNSR compare to MBOT and QTEX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, MBOT (Microbot Medical Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -15.8%, cap $73.2M) and QTEX (QTREX Quantum Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNSR?

▼

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.63 (-0.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-18% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNSR)Realized 20D OHLCV Swing Band: ±7%

Deterministic 5-Pillar Attribution (18/100 Composite)

🔍 WHY LNSR SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (28% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.22-7.6% Next Q

Q2 (-2Q)

Grade E$5.75+3.7% Next Q

Q3 (-1Q)

Grade E$5.96-4.9% Next Q

Current

Grade E$5.67-12.2% Hist 90D α

Trajectory: E (26) → E (18)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LNSR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LNSR currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.04) and Max Pain ($5.95) forces dealer call-delta covering toward $13.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNSR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LNSR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $20,419

Est. Year-10 Shareholder Yield: $123/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.5K

Yr 2

$12.4K

Yr 3

$13.3K

Yr 4

$14.3K

Yr 5

$15.3K

Yr 6

$16.5K

Yr 7

$17.7K

Yr 8

$19.0K

Yr 9

$20.4K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LNSR)

✓Walkthrough of LNSR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LNSR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.98%📐 HORIZONTAL RANGE

2026-11-03O $5.97H $5.97L $5.67C $5.67VOL 28.8K

RES: $11.02SUP: $4.69SMA50: $7.04SMA200: $7.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNSR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LNSR Butterfly Map → + Track LNSR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LNSR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LNSR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LNSR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNSR)

Health Care Rank #1003 of 1015 ⚔️ MBOT vs LNSR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LNSR vs. MBOT, QTEX, SKIN, LUCD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, LENSAR Inc. (LNSR) ranks #1003 by composite RQD confidence (18/100, grade E) and #694 by equity capitalization ($71.7M). Within this direct 5-issuer industry benchmark cohort, LNSR leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. LUCD currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with LNSR at 18/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LNSR ACTIVE LENSAR Inc.	E	18/100	—	39.4%	-35.0%	-2.91%	$71.7M	Benchmark Subject
MBOT Microbot Medical Inc.	E	29/100	—	—	-15.8%	-4.59%	$73.2M	/mbot-vs-lnsr →
QTEX QTREX Quantum Ltd.	D-	36/100	—	0.7%	-35.0%	-8.20%	$68.3M	/qtex-vs-lnsr →
SKIN SkinHealth Systems Inc. (Class A)	E	32/100	—	65.3%	-26.9%	+4.43%	$64.7M	/skin-vs-lnsr →
LUCD Lucid Diagnostics Inc.	D-	39/100	—	—	-35.0%	+0.37%	$82.3M	/lucd-vs-lnsr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001320350 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENSAR Inc. (LNSR) reported GAAP revenue of $51.7M (+12.4% vs. FY2024 revenue of $46.0M , and +44.6% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$14.8M, and free cash flow of -$14.9M (-513.5% YoY). On the balance sheet, LNSR closed FY2025 with $71.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$51.7M	-$34.3M	-$14.8M	-$14.9M	$71.4M	—
FY2024 (FY)	2024-12-31	$46.0M	-$31.4M	-$2.3M	-$2.4M	$66.3M	—
FY2023 (FY)	2023-12-31	$35.7M	-$14.4M	-$9.7M	-$9.7M	—	—

3. LNSR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LNSR compare to MBOT and QTEX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LNSR?

Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?

LNSR last traded at $5.67 (-2.91% on volume of 70,194 shares), positioning the stock -19.46% below its 50-day simple moving average ($7.04) and -23.58% below its 200-day simple moving average ($7.42). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 9.0% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($5.27 to $6.07).

Direct Sub-Reports: LNSR RQD Cockpit LNSR 12M Forecast LNSR Earnings & Move LNSR Dividends & DRIP LNSR Insiders & 13F LNSR Whale Options LNSR Profit Sankey LNSR News & Why

ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

LNSR — LENSAR Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

LENSAR Inc. (LNSR) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.67 (-2.91% 1D, market capitalization $71.7M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 39.4%, operating margin of -47.6%, and free cash flow yield of -20.33%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. — describes its specific products, customers, or revenue model. The profile reports a market capitalization of $0.1B. Reported gross margin is 39.4%, indicating the company retains a portion of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), LENSAR Inc. (LNSR) reported $51.7M in annual revenue (up from $46.0M in FY2024, +12.4% YoY) and -$34.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($35.7M revenue, -$14.4M net income) through FY2025, LNSR scaled operating cash flow to -$14.8M and free cash flow to -$14.9M, backed by $71.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.33% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.95 – $12.94 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -47.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies are mapped (supply_chain: NONE, butterfly_links: empty).

Key Question #1: Can LNSR sustain or expand its -47.6% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $51.7M and free cash flow of -$14.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is LNSR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LNSR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LENSAR Inc. (LNSR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LNSR Debate Forum (3) ↓

🔴 RISK WATCH Stocktwits • 1d ago

Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback

Stocktwits report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

LENSAR, Inc. (LNSR) Seasonal returns chart

Yahoo Finance UK report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

LENSAR, Inc. Estimates – BOATS:LNSR

TradingView report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(LNSR) Movement Within Algorithmic Entry Frameworks

Stock Traders Daily report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

LNSR Q3'26 Earnings: revenue estimate is 14.30M USD

TradingView report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

Why Did NUAI Stock Rise After Hours Today?

Stocktwits report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 2d ago

Price-Driven Insight from (LNSR) for Rule-Based Strategy

Stock Traders Daily report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 2d ago

LNSR Q2 2026 Earnings: EPS Swings to Profit, Beating Estimates by a Wide Margin - Earnings Surprise Stocks

https://www.dars.gov.et/ report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNSR Bull vs. Bear Conversation Board — What's Your Call at $5.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNSR 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $6.83 (+17.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 8/20, the strongest pillar, with revenue growing from $35.7M in FY 2023 to $51

The street is overcomplicating LENSAR Inc. (LNSR). Institutional accumulation and options positioning score 8/20, the strongest pillar, with revenue growing from $35.7M in FY 2023 to $51.7M in FY 2025.. With an RQD score of 18/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.31.

VolSurface_Trader 🐂 BULL

Both sides have a point here — LNSR's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.79 (-18.0%)

Spot @ $5.84

ROIC of -35%, FCF yield of -20.33%, and an Altman Z-Score of 0.2 indicate weak cash generation and elevated forensic balance-sheet risk

Sitting on the sidelines or leaning short LNSR above $5.84. ROIC of -35%, FCF yield of -20.33%, and an Altman Z-Score of 0.2 indicate weak cash generation and elevated forensic balance-sheet risk.. Until Fundamental Cash Engine (2/20) and FCF yield (-20.33%) inflect higher, upside is capped near $12.94.